Tags

Type your tag names separated by a space and hit enter

Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer.

Abstract

OBJECTIVES

Although the association between diabetes mellitus (DM) and pancreatic cancer is well described, temporal patterns of changes in fasting blood glucose (FBG) and body mass index (BMI) before pancreatic cancer diagnosis are not known.

METHODS

We reviewed the medical records of pancreatic cancer cases seen at the Mayo Clinic from 15 January 1981 through to 9 July 2004 and selected those residing within 120 miles of Rochester, MN and who were seen at the Mayo Clinic within 30 days of the date of cancer diagnosis (index date). We identified approximately two matched controls per case residing locally and seen at Mayo in the year of their case index date. For the 736 cases and 1,875 controls with at least one outpatient FBG measurement, we abstracted all FBG values, and corresponding heights and weights up to 60 months before the index date and grouped them into 12-month intervals preceding the index. We compared FBG and BMI in each interval between cases and controls.

RESULTS

Mean FBG values were similar between cases, compared with controls, in the intervals from months -60 to -48 (102 mg per 100 ml vs. 100 mg per 100 ml, P=0.34) and from months -48 to -36 (106 mg per 100 ml vs. 102 mg per 100 ml, P=0.09), but progressively increased in the intervals from months -36 to -24 (105 mg per 100 ml vs. 100 mg per 100 ml, P=0.01), from months -24 to -12 (114 mg per 100 ml vs. 102 mg per 100 ml, P=0.001), and from months -12 to +1 (123 mg per 100 ml vs. 102 mg per 100 ml, P<0.0001). Though mean BMI values were generally similar in cases and controls up to 12 months before index, they were significantly lower in cases vs. controls in the interval from months -12 to +1 (P<0.001).

CONCLUSIONS

Pancreatic cancer is characterized by progressive hyperglycemia beginning up to 24 months before cancer diagnosis in the setting of decreasing BMI. Pancreatic cancer can potentially be diagnosed early if biomarkers are identified that can distinguish pancreatic cancer-induced DM from type II DM.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Gastroenterology and Hepatology, Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA.

    , , , , , ,

    Source

    MeSH

    Aged
    Blood Glucose
    Body Mass Index
    Case-Control Studies
    Disease Progression
    Female
    Humans
    Hyperglycemia
    Male
    Middle Aged
    Pancreatic Neoplasms
    Retrospective Studies
    Time Factors

    Pub Type(s)

    Journal Article
    Research Support, N.I.H., Extramural

    Language

    eng

    PubMed ID

    19513024

    Citation

    Pannala, Rahul, et al. "Temporal Association of Changes in Fasting Blood Glucose and Body Mass Index With Diagnosis of Pancreatic Cancer." The American Journal of Gastroenterology, vol. 104, no. 9, 2009, pp. 2318-25.
    Pannala R, Leibson CL, Rabe KG, et al. Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am J Gastroenterol. 2009;104(9):2318-25.
    Pannala, R., Leibson, C. L., Rabe, K. G., Timmons, L. J., Ransom, J., de Andrade, M., ... Chari, S. T. (2009). Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. The American Journal of Gastroenterology, 104(9), pp. 2318-25. doi:10.1038/ajg.2009.253.
    Pannala R, et al. Temporal Association of Changes in Fasting Blood Glucose and Body Mass Index With Diagnosis of Pancreatic Cancer. Am J Gastroenterol. 2009;104(9):2318-25. PubMed PMID: 19513024.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. AU - Pannala,Rahul, AU - Leibson,Cynthia L, AU - Rabe,Kari G, AU - Timmons,Lawrence J, AU - Ransom,Jeanine, AU - de Andrade,Mariza, AU - Petersen,Gloria M, AU - Chari,Suresh T, Y1 - 2009/06/09/ PY - 2009/6/11/entrez PY - 2009/6/11/pubmed PY - 2009/10/2/medline SP - 2318 EP - 25 JF - The American journal of gastroenterology JO - Am. J. Gastroenterol. VL - 104 IS - 9 N2 - OBJECTIVES: Although the association between diabetes mellitus (DM) and pancreatic cancer is well described, temporal patterns of changes in fasting blood glucose (FBG) and body mass index (BMI) before pancreatic cancer diagnosis are not known. METHODS: We reviewed the medical records of pancreatic cancer cases seen at the Mayo Clinic from 15 January 1981 through to 9 July 2004 and selected those residing within 120 miles of Rochester, MN and who were seen at the Mayo Clinic within 30 days of the date of cancer diagnosis (index date). We identified approximately two matched controls per case residing locally and seen at Mayo in the year of their case index date. For the 736 cases and 1,875 controls with at least one outpatient FBG measurement, we abstracted all FBG values, and corresponding heights and weights up to 60 months before the index date and grouped them into 12-month intervals preceding the index. We compared FBG and BMI in each interval between cases and controls. RESULTS: Mean FBG values were similar between cases, compared with controls, in the intervals from months -60 to -48 (102 mg per 100 ml vs. 100 mg per 100 ml, P=0.34) and from months -48 to -36 (106 mg per 100 ml vs. 102 mg per 100 ml, P=0.09), but progressively increased in the intervals from months -36 to -24 (105 mg per 100 ml vs. 100 mg per 100 ml, P=0.01), from months -24 to -12 (114 mg per 100 ml vs. 102 mg per 100 ml, P=0.001), and from months -12 to +1 (123 mg per 100 ml vs. 102 mg per 100 ml, P<0.0001). Though mean BMI values were generally similar in cases and controls up to 12 months before index, they were significantly lower in cases vs. controls in the interval from months -12 to +1 (P<0.001). CONCLUSIONS: Pancreatic cancer is characterized by progressive hyperglycemia beginning up to 24 months before cancer diagnosis in the setting of decreasing BMI. Pancreatic cancer can potentially be diagnosed early if biomarkers are identified that can distinguish pancreatic cancer-induced DM from type II DM. SN - 1572-0241 UR - https://www.unboundmedicine.com/medline/citation/19513024/Temporal_association_of_changes_in_fasting_blood_glucose_and_body_mass_index_with_diagnosis_of_pancreatic_cancer_ L2 - http://Insights.ovid.com/pubmed?pmid=19513024 DB - PRIME DP - Unbound Medicine ER -